• Share
  • Email
  • Embed
  • Like
  • Save
  • Private Content
Ind prof bio_2010_bio_1011_ip02
 

Ind prof bio_2010_bio_1011_ip02

on

  • 556 views

 

Statistics

Views

Total Views
556
Views on SlideShare
556
Embed Views
0

Actions

Likes
0
Downloads
1
Comments
0

0 Embeds 0

No embeds

Accessibility

Categories

Upload Details

Uploaded via as Adobe PDF

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

    Ind prof bio_2010_bio_1011_ip02 Ind prof bio_2010_bio_1011_ip02 Document Transcript

    • Si n g a p o r e B i o t ech G u i d e 2 0 1 0 / 2 0 1 1 Overview of Singapore’s Pharmaceutical and Biotechnology IndustryAsia Presents New Growth Key advantages include:Opportunities • World’s Easiest Place to Do Business Asia’s healthcare market is valued at US$240 (World Bank, 2009) – Singapore has billion in the year 2008 and is expected to established a strong legal system andgrow between 5% to 10% (Frost & Sullivan, a stable political system that prides2009). While Asia presents a dynamic and itself on honesty, quality and reliability.fresh playing field that offers tremendous At the same time, the city-state offersopportunities for those who dare to think an international business environmentdifferently, its diversity in political systems, with the world’s global industry leadersculture and economic development constitute setting up business activities that includechallenging new grounds. Success will thus headquarters, R&D and manufacturing. depend on an in-depth understanding of local Leveraging its world-class infrastructureconditions and regulatory regimes. and reliable public utilities, Singapore presents a trusted location to manageDriving Expansion in Asia companies’ business expansion whileLocated in the heart of Asia, Singapore is a being attuned with global developments.choice location for companies’ internationaland regional headquarters to drive global • Excellent Connectivity – Singapore is well companies’ expansion into Asia and Asian connected with regional markets withincompanies’ global outreach. seven-hour flight radius. As a leading 13
    • S inga po r e Bio t ec h G u ide 2010/ 2011 aviation hub in Asia, Singapore’s Changi Airport serves over 80 international airlines, with over 4,500 flights each week, connecting to 190 cities in more than 60 countries. Coupled with its world- class infrastructure, Singapore has been a location of choice for companies to host regional meetings and conferences. Furthermore, Singapore is connected to the most extensive network of Free Trade Agreements (FTAs) in Asia, having concluded 19 FTAs that cover 60% of the world’s GDP.• Access to Talent – Singapore offers top production plants, Singapore presents a quality of life in Asia (Mercer HR, 2009) reliable manufacturing site where they can and has drawn both global and regional effectively transfer technology, efficiently talent, who seek to experience the best scale-up manufacturing and ensure quality international experience at the cultural control of their products. Today, leading crossroads of the East and the West. pharmaceutical and biotechnology companies Singapore’s safe environment and its have invested in 30 commercial-scale base of renowned international schools facilities, where some of their most innovative have also made it easier for executives to medicines are produced. relocate their families. Some of the key benefits of manufacturing in Leveraging Singapore’s advantages, 30 Singapore include:leading biomedical sciences companies haveset up regional and international headquarters • Rapid set-up and export – Companies in Singapore. In 2009, Takeda opened its setting up in Singapore can construct andregional headquarters in Singapore to drive its validate a manufacturing plant within 24-commercial growth and reach in Asia Pacific; 36 months, given the city-state’s qualityQuintiles also doubled the size of its Asia- manpower, world-class infrastructure andPacific headquarters to an 80,000 square-feet reliable supporting services. In addition,facility to meet the region’s growing demand. Singapore has established a good track record with regulatory authorities, asManufacturing Innovative Medicines well as strong trade linkages with majorAs global companies seek to manage their markets. Together with its excellentrisks by diversifying the geography of their logistics connectivity, companies can14
    • Si n g a p o r e B i o t ech G u i d e 2 0 1 0 / 2 0 1 1 quickly export and distribute their address manpower issues harmoniously. products to global markets. Manpower costs remain competitive with entry salaries for B.Eng graduates pegged • Pro-Business Environment – Singapore at US$1,500 each month for about 50 is well-known for its business-friendly working hours each week. environment, with its good corporate governance, clear and consistent • Industry’s partner in process development government guidelines and excellent – Companies (e.g. GlaxoSmithKline, IP protection. Singapore also offers a Novartis) are extending beyond commercial politically stable and favourable tax manufacturing into process development. environment. This ease of doing business In addition to setting up their own is complemented by the country’s support process development units, companies for the adoption of environmentally- can also partner our research institutes friendly practices and technologies in the (e.g. Institute of Chemical Engineering manufacturing sector. and Sciences, Bioprocessing Technology Institute) to optimise manufacturing• Quality Manpower – Singapore offers processes and the formulation of new a base of skilled local talent who are products. The Singapore Institute of well-trained in science and mathematics. Manufacturing Technology has partnered Singapore’s workforce is consistently companies to develop automation ranked the world’s best labour force solutions to streamline operations. (BERI). Since the 1970s, the city-state has had zero man-days loss on strikes, due to Singapore is strengthening its position its tripartite system that brings together as Asia’s leading site for biopharmaceutical the government, employers and unions to manufacturing. In 2009, leading companies located their first-in-Asia facilities in Singapore – GlaxoSmithKline opened its vaccine plant that will produce purified bulk polysaccharides and conjugates which are used to manufacture GSK’s new pneumococcal conjugate vaccine, meningitis, and other new innovative vaccines; Baxter commenced construction for its Advate plant; Roche purchased Lonza’s mammalian- cell facility to manufacture Avastin and officially opened its microbial-cell facility to manufacture Lucentis. Singapore also made headway in cell therapy with Lonza’s first-in- Asia cell therapy plant. 15
    • S inga po r e Bio t ec h G u ide 2010/ 2011 Within five years since the first biologics companies to carry out candidate to proof-announcement, leading companies have of-concept activities. Complementing these invested about US$2 billion in six major advantages with Singapore’s establishedplants. In 2009, Millipore set up its first base of contract research organisations andregional training centre for biopharmaceutical global central labs, Singapore presents amanufacturing, in response to the growing one-stop location for companies to carry outbase of biologics plants in Singapore. drug discovery and development activities. In addition, Singapore’s focus on diseases Building on our strong track record for prevalent in Asia and its base of globalchemical-based pharmaceutical and biologics researchers will help to accelerate companies’manufacturing, Singapore is building innovation for the fast-growing Asianup capabilities in process development markets.and green manufacturing. In 2009,Bioprocessing Technology Institute partnered Singapore has developed the followingGlaxoSmithKline Biologicals for vaccine capabilities and resources that enableand process development. GlaxoSmithKline companies to accelerate drug discovery andalso announced a S$50 million endowment development in Asia:fund, jointly launched with the EDB, to fund graduate studies in green manufacturing and • Integrated Countrywide Research public health policy. Network – Global biomedical sciences companies are leveraging Singapore’sAccelerating Drug Discovery & integrated countrywide network thatDevelopment connects research institutes at theSingapore has established world-class Biopolis with Academic Medical Centres scientific and clinical excellence, which enables (AMC), where public hospitals and 16
    • Si n g a p o r e B i o t ech G u i d e 2 0 1 0 / 2 0 1 1 • Regulatory Framework that facilitates innovation – Singapore seeks to achieve a regulatory framework that facilitates the development of innovative therapies, while ensuring global standards of safety, quality and efficacy. The Singapore’s Health Sciences Authority (HSA) is actively involved in defining new regulatory frameworks and pursuing new areas of research in regulatory science. HSA hosted the 3rd Summit of Heads of Medicines Regulatory Agencies in December 2008 and will co-host the 14th International medical institutes that attend to 80% of Conference of Drug Regulatory Authorities Singapore’s patients and Investigational with World Health Organisation (WHO) in Medicine Units (IMUs) are co-located September 2010. HSA has also forged with institutes of higher learning. This MOUs with world’s leading regulatory integration not only enables an efficient agencies such as the US Food and Drug flow of knowledge from the bench to the Administration, China’s State Food and bedside; equally importantly, it provides a Drug Administration and UK’s Medicines platform for clinician-scientists to address and Healthcare Products Regulatory hypotheses derived from the bedside. Agency. In October 2009, Singapore was accepted into OECD’s Mutual Acceptance • Excellent Intellectual Property Protection of Data framework that enables data – Building on its world-class legal system, from GLP-compliant pre-clinical trials Singapore ranks no. 1 in the world for conducted in Singapore to be accepted by intellectual property (IP) protection (World 30 OECD and non-OECD members that Economic Forum Global Competitiveness include the U.S., EU and Japan. Report 2009-2010). Singapore has signed major international IP conventions and • Plugged into Asia – Located at the treaties that allow IP filed here to receive heart of Asia, Singapore offers excellent global protection. Singapore has also connectivity to key Asian markets and established an extensive infrastructure provides medical insights from its pan- with professional consultancies and Asian population base. In 2006, Singapore institutes that provide advisory services launched the Translational and Clinical for IP management. In 2005, the World Research (TCR) Flagship programmes that Intellectual Property Office set up its first present a key platform for researchers and Asian regional office in Singapore. clinician-scientists to develop therapies 17
    • S inga po r e Bio t ec h G u ide 2010/ 2011 for key diseases relevant to Singapore and Asia. Companies can carry out pre-clinical and first-in-man trials for drug candidates that are developed outside Singapore, and manage later-phase trials in Asia from in- house control tower units or via CROs in Singapore.• Access to Global Talent – To continually grow its pool of global biomedical talent, Singapore is committed to driving innovation and offers a high standard of living that is comparable to leading cities worldwide. Today, 4,000 international and hospitals in Singapore. These companies and local researchers carry out include Abbott, GlaxoSmithKline, Novartis, biomedical sciences R&D in Singapore. Lilly, Schering-Plough, Takeda, S*Bio, Local researchers make up about 70% Inviragen, MerLion Pharmaceuticals and of the private-sector researcher pool, PharmaLogicals. and top scientists have relocated to Singapore to lead our research institutes. Recent announcements include Schering- In addition, leading pharmaceutical and Plough’s Translational Medicine Centre and biotech companies have teams with Abbott’s pharmaceutical analytical research an international representation in their lab. Recent biotech announcements include Singapore corporate labs. The Novartis S*BIO’s licensing agreements with Onyx and Institute for Tropical Diseases, for example, Tragara to develop oncology drugs, which will employs more than 100 researchers from entitle S*BIO to receive more than US$600 18 nationalities. million in payment; FORMA Therapeutics’ first overseas lab in Nanyang Technological Singapore’s efforts to build up core University, Singapore; Inviragen’s merger with capabilities in basic science as well as SingVax, which raised US$15 million in Seriestranslational and clinical research have A financing.provided us with a strong scientific base toengage leading pharmaceutical and biotech Complementing Singapore’s strengths in companies in collaborative R&D activities. early innovation and translational research, the city-state has also established a core base Today, more than 50 biomedical sciences of 20 leading contract research organisationscompanies are carrying out R&D alongside (CROs) and pharmaceutical companies that 30 research institutes, medical institutes manage regional clinical trials from Singapore.18
    • Si n g a p o r e B i o t ech G u i d e 2 0 1 0 / 2 0 1 1Recent announcements in the year 2009 Singapore to head the city-state’s researchinclude Takeda’s regional clinical coordination institutes, consortia and laboratories.centre, ICON’s expanded central lab, PPD’s new Singapore is now home to more than 2,000global central lab and Quintiles’ expansion of researchers from across the globe.its Asia-Pacific headquarters facility. Singapore provides an enticingAccessing Global Talents environment for professionals, and hasSingapore is well-known for its ability been consistently ranked as Asia’s topto attract the world’s top scientific and city in terms of quality of life (Mercer HR; business talents. Edward Holmes (former ECA International) and offers an excellent Vice Chancellor, University of California, San education system. The city-state is English-Diego), Judith Swain (University of California, speaking, cosmopolitan with foreignersSan Diego), Edison Liu (former director of making up a quarter of the population, andclinical sciences, National Cancer Institute, offers a range of dynamic entertainment andUS), Neal Copeland and Nancy Jenkins recreation options. Since 2008, Singapore has(National Cancer Institute, US), Sir George been hosting Formula One’s first night race Radda (former Chief Executive, Medical during Singapore Grand Prix. In 2010, two Research Council), Colin Blakemore (UK integrated resorts, which host world-classMedical Research Council), Axel Ulrich (Max hotel, convention, entertainment facilitiesPlanck Institute for Biochemistry, Germany), and a casino in one location, will officiallyPhilippe Kourilsky (College de France, France), open. These resorts are developed by LasSydney Brenner (Nobel Laureate, Salk Vegas Sands and Genting International.Institute of Biological Sciences), and Yoshiaki Singapore is also within a seven hourIto (University of Kyoto, Japan) are amongst flight radius from the region’s top touristthe scientific leaders who have come to destinations (e.g. Angkor Wat in Cambodia, Bali in Indonesia, Hua Hin and Phuket in Thailand, Shangri La in China). Singapore also recognises the need to nurture the next generation of scientists. Since the year 2001, Singapore’s Agency for Science, Research and Technology (A*STAR) has launched a national scholarship programme that seeks to nurture 1,000 local PhD graduates in the world’s top universities. To date, A*STAR has awarded more than 500 biomedical sciences scholarships. More than 100 19
    • S inga po r e Bio t ec h G u ide 2010/ 2011awardees have completed their PhDs and returned to work in A*STAR research institutes and units. In addition, Singapore has launchedthe A*STAR Investigatorship (A*I) award, which was modeled after the prestigiousHoward Hughes Medical Institute (HHMI)Investigatorship award, to attract brightyoung researchers to carry out independentresearch in Singapore’s public-sector researchinstitutes. Bruno Reversade (France) and Prabha Sampath (India) are the first recipients of the award. In September 2009, Reversade Key highlights in 2009 include Lonza’sled a group of German and Singaporean foray into cell therapy after investing in thescientists to publish their findings in genetic first biologics plants in Singapore; Baxter’s mutation that led to premature skin ageing expansion from 30-years of medical devicein the prestigious Nature Genetics. and implantable manufacturing into biopharmaceutical manufacturing; GSK’s Besides basic researchers, Singapore has partnership with EDB in launching the S$50 also introduced various schemes to grow our million endowment fund for graduate studiescadre of clinician scientists. The Singapore in green manufacturing and public healthTranslational Research Investigator Award policy, on the occasion of its 50th anniversary(STaR) is designed to recruit and nurture of doing business in Singapore.world-class clinician scientists to undertakecutting-edge translational and clinical As global pharmaceutical andresearch in Singapore; the Clinician Scientist biotechnology companies seek to locate theirAward (CSA) is another scheme that provides key business functions and decision makersfunding and salary support for clinicians closer to the fast-growing Asian markets,to allocate at least 70% of their time on Singapore presents a strategic base as theseresearch. companies’ home-base for the business expansion and innovation in Asia.Forging Long-Standing PartnershipsSingapore is committed to be in time forthe future and is committed to partneringcompanies to co-create solutions to addressunmet healthcare needs in Asia and the Contributed by the Singapore Economic industry’s challenges. Development Board20